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Widespread metastasis is the leading course of death in many types of cancer, including
malignant melanoma. The process of metastasis can be divided into a number of complex
cell biological events, collectively termed the “invasion-metastasis cascade.” Previous
reports have characterized the capability of anchorage-independent growth of cancer
cells in vitro as a key characteristic of highly aggressive tumor cells, particularly with
respect to metastatic potential. Biological heterogeneity as well as drastic alterations in
cell adhesion of disseminated cancer cells support escape mechanisms for metastases
to overcome conventional therapies. Here, we show that exclusively the carcinoembry-
onic antigen-related cell adhesion molecule 1 (CEACAM1) splice variant CEACAM1-4L
supports an anchorage-independent signature in malignant melanoma. These results
highlight important variant-specific modulatory functions of CEACAM1 for metastatic
spread in patients suffering malignant melanoma.
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Metastatic melanoma is a devastating disease of increasing incidence. Tumor progression starts
very early in this disease, resulting in a median survival of 6–12months in patients with advanced
melanoma (1). Melanoma cell metastasize predominantly via tumor-associated lymphatic vessels
to regional lymph nodes, and subsequently, lymph node metastasis is a major determinant for the
staging and clinical management of melanoma (2). Thus, the main cause of death in melanoma
patients is widespread metastases that show often resistance to current therapies. To this end,
extensive efforts have been made to understand the cellular and molecular processes underlying the
metastatic cascade for further development of therapeutic approaches directed against disseminated
disease. The first step of the metastatic cascade occurs in the primary tumor, where subpopulations
of cancer cells lose their cell–cell contact, exit the tumor mass and invade locally through the
extracellular matrix and tumor-associated stromal cell layers. Subsequently, cancer cells intravasate
into the microvasculature of the blood or lymphatic system, survive in the circulation, extravasate
into the parenchyma of distant organs and adapt to the foreign microenvironment in order to form
metastases (3). Dysregulation of cell adhesion molecules has already been associated with disease
progression inmalignant melanoma (4). In this context, evidence has amassed that expression of the
multi-functional cell–cell adhesion protein CEACAM1 may be involved in the multistep process of
metastatic spread in melanoma (5). CEACAM1, a transmembrane protein of the CEA family within
the immunoglobulin superfamily (6), has been shown to be expressed in various human epithelial
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(7, 8), activated endothelial (9), and on a variety of hematopoietic
cells (10, 11). Mainly four CEACAM1 isoforms are known to be
co-expressed in human tissue with either three (CEACAM1-3)
or four (CEACAM1-4) highly glycosylated extracellular Ig-like
domains, a single-pass transmembrane domain and either a short
(S) or long (L) cytoplasmic tail (12). It has already been described
that the long cytoplasmic domain, in contrast to the short ver-
sion, contains two ITIM motifs, which play an important role
for the initiation of cellular signaling (13). CEACAM1 has been
controversially discussed as tumor suppressor but also as driver
for invasion in different tumor entities (14, 15). Loss or lower level
of CEACAM1 expression has been detected in colon (16), prostate
(17), and breast cancers (18), whereas high expression levels have
been found in adenocarcinomas (19), non-small lung cancers
(20), and melanoma (21). In addition, the CEACAM1 expression
in confluent, contact-inhibited, and proliferating epithelial cells
differs significantly with respect to the amount and isoform ratio
(22, 23). Beside the membrane anchored CEACAM1 variants,
also soluble and microvesicle-bound versions were described (24,
25). Interestingly, the CEACAM1 expression levels in biopsies
(26) and concentrations of soluble CEACAM1 in sera (27, 28)
of melanoma patients have been reported as a strong clinical
predictor of poor prognosis and high risk of metastasis. In con-
sequence, recent studies discuss CEACAM1 as a novel diagnostic
and therapeutic target in patients of malignant melanoma.
Recent studies identified the long cytoplasmic domain of CEA-
CAM1 (CEACAM1-L) as driver for invasion in hepatocellular
carcinoma (29) and colon cancer (30). Nevertheless, most stud-
ies in melanoma were focused on overall CEACAM1 without
distinguishing the different isoforms. Generating transfectants
explicitly expressing just a single splice variant of CEACAM1 in
the human melanoma cell line, Ma-Mel-86a (Figures S1A,B in
Supplementary Material) we recently identified, that CEACAM1
expression impacts melanoma progression and antitumor immu-
nity in a variant-specific mode of action (31). Previous reports
identified cancer cells with metastatic potential by their ability to
exhibit anchorage-independent growth (colony forming capacity
in semisolid media), a phenotype, which has also been described
as a crucial marker for in vitro transformation (32). Since studies
exploring the impact of the four different CEACAM1 isoforms
within the context of metastatic cancer cell dissemination are
completely missing, we now validated the signature of each splice
variant with respect to their colony forming capacity. Strikingly,
we could detect variant-specific changes in the capacity to grow
in vitro under anchorage-independent conditions by analyzing the
CEACAM1 isoform transfectants, whereas expression of exoge-
nous CEACAM1-3S leads to initial tumor cell assembling in
semisolid media but diminished the formation of proliferative
colonies, indicated by the reduced colony size (Figures 1A,B).
Furthermore, expression of CEACAM1-4S significantly damp-
ens the number of colonies (Figure 1B), while CEACAM1-3L
does not affect this phenotypic signature. Interestingly, among
all isoforms, only CEACAM1-4L expression results in a signifi-
cant increase in colony size when compared to the empty vec-
tor control (Figure 1B) while the total number of colonies was
not altered. In order to exclude off-target-effects caused by the
expression of CEACAM1-4L, we performed a RNAi approach
in pCL6-CEACAM1-4L-IRES-eGFP (pCL6-CC1-4L-IEG) over-
expressing cells using control and CEACAM1 specific shRNA
(for details, please see Materials and Methods). CEACAM1 over-
expression and the knock-down were confirmed by Western
Blot analysis (Figure 1C). As expected, the mean colony size
was significantly reduced when cells where grown in a soft agar
assay, indicating a crucial rule of CEACAM1-4L in anchorage-
independent growth in malignant melanoma, which was further
verified by the knock-down of endogenous CEACAM1 in UKRV-
Mel-15a cells (Figure 1D). As metastatic spread is associated with
loss of adhesion, we performed adhesion assays using lentiviral-
induced expression of pCL6-CEACAM1-4L-IRES-eGFP (pCL6-
CC1-4L-IEG) in UKE-Mel-1a cells, a further cell line without
endogenous CEACAM1-expression. In line with the increase
in anchorage-independent growth pCL6-CC1-4L-IEG expression
revealed reduced adhesion to collagen I when compared to mock
control cells (pCL6-IEG) and this effect was reversed by the
knock-down of CEACAM1 (Figure 1E). Together these data indi-
cate a crucial role of CEACAM1-4L in the initiation of metastatic
processes in malignant melanoma.
Although multiple genetic factors for anchorage independency
have been identified so far (32, 33), the detailed molecular sig-
nature for this phenotypic behavior is largely unknown. To our
understanding, tumor cells identified for their highly aggres-
sive signature, e.g., anchorage-independent growth, should also
present a highly invasive phenotype which has been shown to
correlate with changes in the tumor secretome. Consequently, we
used a ProteomeProfiler AntibodyArray to analyze changes in the
expression of soluble factors in all CEACAM1 isoform transfec-
tants. This analysis revealed distinct and significant changes in the
expression of factors associated with matrix metalloproteinases
(MMP) expression and activation, including uPAR, RANTES,
IL-6, and EMMPRIN, in particular in CEACAM1-4L expressing
cells (34–37) (Figure 2A). In contrast, some other factors includ-
ing e.g., theMacrophagemigration inhibitory factor (MIF; mainly
involved in immune response) and the Wnt-signaling involved
factor Dickkopf-1 (DKK1), are almost equally up-regulated by
the expression of all CEACAM1 isoforms when compared to
cells lacking CEACAM1 expression. It has been well established
that the invasive phenotype of melanoma cells, is associated with
the expression of MMPs. In particular, the gelatinase MMP-2
and their endogenous inhibitors, the tissue inhibitor of MMPs
(TIMPs), drive degradation of stromal compartments for can-
cer cell invasion (38, 39). Activation of proMMP-2 (the inactive
form of MMP-2) occurs primarily via the formation of a tri-
molecular complex consisting of the membrane bound MMP-
14, a protease already characterized for their impact on colony
formation (40), TIMP-2 and MMP-2 (41, 42). In this regard, we
were not surprised to detect significant induction of MMP-2 and
MMP-14 mRNA expression in the CEACAM1-4L transfectants
(Figure 2B). In accordance with these findings, high levels of
MMP-14 resulted in enhanced cleavage and proteolytic activity of
MMP-2 in the human Ma-Mel-86a melanoma cell line express-
ing CEACAM1-4L (Figure 2C), which in consequence, drives
these cells to grow under anchorage-independent conditions.
In line, CEACAM1-3S and CEACAM1-4S transfectants, which
failed to generate growing colonies in semisolid media, possessed
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FIGURE 1 | (A,B) Influence of CEACAM1 splice variants on anchorage-independent growth of melanoma cells. The cell line Ma-Mel-86a was transfected with empty
vector (pcDNA3.1), CEACAM1-3L (CC1-3L), CEACAM1-3S (CC1-3S), CEACAM1-4L (CC1-4L), and CEACAM1-4S (CC1-4S) and cultured in soft agar for 14 days.
(A) Representative images are shown. Scale bar, 100μm. (B) Quantitative assessment for the number and diameter of colonies formed by CEACAM1 isoform
transfectants. Colonies in the area of 1 cm2 were measured. Shown are mean values of three independent experiments. (C) Ma-Mel-86a cells were transduced with
viral particles containing either the empty vector pCL6-IRES-eGFP (pCL6-IEG) or pCL6-CEACAM1-4L-IRES-eGFP (pCL6-CC1-4L-IEG). pCL6-CC1-4L-IEG
expressing cells were further transfected with scrambled (sc) or CEACAM1 (CC1) specific shRNA. Stable expression of pCL6-CC1-4L-IEG was analyzed by Western
Blot (left panel). Beta-actin was used as loading control. Ma-Mel-86a pCL6-CC1-4L-IEG cells transfected with sc or CC1 shRNA were cultured in soft agar for
7 days. Graph shows quantitative assessment of colony diameter. (D) UKRV-Mel-15a cells were transfected with sc or CC1 shRNA. Expression of endogenous
CEACAM1 was analyzed by Western Blot (left panel). Beta-actin was used as loading control. These cells were cultured in suspension for 5 days. Graph shows
quantitative assessment of colony diameter. *p<0.05, ***p<0.001, (E) UKE-Mel-1a cells were transduced with viral particles containing either pCL6-IRES-eGFP
(pCL6-IEG) or pCL6-CEACAM1-4L-IRES-eGFP (pCL6-CC1-4L-IEG). pCL6-CC1-4L-IEG expressing cells were further transfected with scrambled (sc) or CEACAM1
(CC1) specific shRNA. All cell lines were allowed to adhere to collagen I for 45min.
decreased MMP-2 activity (Figure 2C). In order to analyze the
functional involvement of MMPs in the anchorage-independent
proliferation, we grew Ma-Mel-86a CEACAM1-4L transfectants
in the presence or absence of MMP-inhibitors. Indeed, treatment
with the MMP-2 specific inhibitor ARP 100 resulted in signifi-
cant reduction of the mean colony size (Figure 2D), indicating
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FIGURE 2 | Involvement of MMPs in anchorage-independent growth of CC1-4L transfectants. (A) Analysis of factors secreted into the medium by
CEACAM1 isoform expressing melanoma cells. Conditioned media were prepared as described in Section Materials and Methods and applied to a Proteome Profiler
Antibody Array. Graph shows the quantification of indicated soluble factors as mean pixel density quantified using ImageQuant software. Data were normalized to the
signals of the pcDNA3.1 transfectants. (B) CEACAM1 splice variant transfectants were analyzed for MMP-2 and MMP-14, expression by qRT-PCR. Shown are mean
values of three to four independent experiments. *p<0.05, **p<0.01. (C) Detection of MMP-2 activity in supernatant obtained from indicated CEACAM1 splice
variant transfectants by gelatin zymography. Equal amounts of conditioned media (normalized to cell number) were separated on SDS-gelatin zymography. The
inactive (pro-) and active forms of MMP-2 are depicted on the right. One experiment out of three independent analyses is shown. (D) Ma-Mel-86a CC1-4L
expressing cells were cultured 2 days in the presence of DMSO (Ctrl), MMP-2-specific inhibitor (ARP 100) (13 nM), or Marimastat (2μM) before embedding into soft
agar. DMSO and inhibitors were inoculated into the top agar and added to the covering medium. Medium was changed every second day. Single cells were allowed
to form colonies for 7 days. Graph shows quantitative assessment of colony diameter. *p<0.05, ***p<0.001.
that the increase in anchorage-independent proliferation partially
depends on the activation of pro-MMP-2 in the presence of the
CEACAM1-4L splice variant. However, since the broad MMP
inhibitor, Marimastat showed potential to enhance this effect, we
conclude that also further MMPs influence this cellular behavior
and are connected to the interplay with CEACAM1-4L.
Taken together, we showed that CEACAM1 splice variants act
in an antagonistic fashion by modulating phenotypic signatures
involved in metastatic dissemination of melanoma cells. These
observations highlight the significance of the variant-specific
function of CEACAM1 for melanoma progression. Nevertheless,
our findings warrant further mechanistic analysis to focus on the
molecular crosstalk betweenCEACAM1 andmolecules, known to
be involved in the metastatic cascade of melanoma cells. This may
offer new insights for novel therapeutic approaches in melanoma
patients.
MATERIAL AND METHODS
Cells and Cell Culture
The cell line Ma-Mel-86a and UKE-Mel-1a were established from
nodal metastasis and UKRV-Mel-15a generated by using a skin
metastasis of stage III melanoma patients [according to the AJCC
criteria (43)].
All cell lines were provided by the Skin Cancer Biobank
(SCABIO) of the Dermatology Department, University Hospi-
tal Essen, Germany. Patient informed consent was obtained and
studies were approved by the Institutional Review Board. Clinical
information such as age, gender, stage of disease, and survival
time were documented and retrieved from the database (Achiver
Anyware Medical, Achiver Software). RPMI 1640 (Ma-Mel-86a
andUKRV-Mel-15a) orDMEM(UKE-Mel-1a)was supplemented
with 10% fetal calf serum (FCS), 1% Penicillin/Streptomycin,
and 1% -Glutamine (all from PAA Laboratories) and used for
cultivation at 37°C and 5% CO2. Cells were regularly tested for
mycoplasma contamination.
Reagents
The MMP-2 specific inhibitor ARP 100 was obtained from Santa
Cruz.Marimastat was obtained fromCalbiochem.All compounds
were applied in the indicated concentrations.
Plasmid Constructs and Transfection
The coding region of human CEACAM1-3L (NM_001184813.1),
CEACAM1-3S (NM_001184816.1), CEACAM1-4L (NM_
001712.4), and CEACAM1-4S (NM_001024912.2) were cloned
into the pcDNA3.1( ) Neo expression vector (Invitrogen) and
verified by sequencing. Constructs were transfected into the
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Ma-Mel-86a cell line using Metafectene (Biontex) according
to manufacturer’s protocol. Afterward, single clones were
established and selectively grown in medium containing 1mg/ml
G418 (Carl Roth). For construction of lentiviral constructs with
eGFP reporters, the coding region of the CEACAM1-4L isoform
was subcloned into pCL6-IRES-EGwo plasmids (44) via XhoI
and EcoRI.
Lentiviral Transduction
Lentiviral supernatants were generated as described previously
(45). Briefly, HEK293T cells were co-transfected with either
pCL6-IRES-eGFPwo (pCL6-IEG, control) or pCL6-CEACAM1-
4L-IRES-eGFPwo plasmids (pCL6-CC1-4L-IEG), together with
the pCD/NL-BH helper plasmid (46) and the codon-optimized,
human foamy virus envelope expression plasmid pcoPE (47)
using Jetpei (Polyplus, IllkirchCedex, France) transfection reagent
according to the manufacturer’s recommendations. Gene expres-
sion from the human cytomegalovirus (CMV) immediate-early
gene enhancer/promoter was induced 24 h after transfection with
10mM sodium butyrate. Forty-eight hours after transfection,
supernatants were collected, filtered through 0.45-μm filters (Sar-
torius), concentrated by centrifugation at 25,000 g for 90min at
4°C and stored at  80°C. Virus stocks were titrated on HEK293T
cells before use.
Ma-Mel-86a and UKE-Mel-1a cells were transduced by
overnight exposure to virus stocks, passaged at least twice, and
subsequently sort-purified (eGFP expression) on a BD FACSAria
IIIu cell sorter. The established cell line was passaged at least
5 times before experiments were performed.
CEACAM1 shRNA
Knock-down of either endogenous CEACAM1 in UKRV-Mel-
15a cells or of over-expressed pCL6-CEACAM1-4L-IRES-eGFP
(pCL6-CC1-4L-IEG) in Ma-Mel-86a and UKE-Mel-1a cells
was performed by transfecting SureSilencing shRNA Plasmid
(Hs.512682) (Quiagen) using jetPRIME transfection reagent
(Polyplus) according to the manufacturer’s recommendations.
Negative control shRNA vector (scrambled artificial sequence)
was used as control (Quiagen). To generate stable clones lacking
CEACAM1 expression, transfected melanoma cells were selected
in 1mg/ml of G418.
RT-PCR and qRT-PCR
Total RNA was isolated and c-DNA was synthesized as described
before in Ref. (48). All semi-quantitative RT-PCRs were
performed in linear range of amplification and 1μg cDNA was
used as template. Following primers were utilized: Actin forward
50-ACCCTGAAGTACCCCAT-30, reverse 50-TAGAAGCATTTG
CGGTG-30; CEACAM1 splice variants forward 50-AACCAAA
GCGACCCCATCA-30, reverse 50-RTGGGTCATTGGAGTGG
TCC-30. Isoform specific amplification products (bp):
CEACAM1-4L= 779; CEACAM1-4S= 726; CEACAM1-3L=
491 bp; CEACAM1-3S= 438. Quantitative RT-PCR was
performed using specific TaqMan Gene Expression assays
in combination with the StepOnePlus Real-Time PCR system
(Applied Biosystems). Relative fold change was calculated by
the 2 ΔΔCt method after normalizing the Ct values to GAPDH.
ΔCt-values were used for statistically evaluation.
Western Blot
Proteins were extracted from melanoma cells using Cell Lysis
Buffer® (Cell Signaling) and separated by SDS-PAGE. Proteins
were transferred onto nitrocellulose membranes and probed with
mouse anti-human Actin (MP Biomedicals) and mouse anti-
human CEACAM1 (clone 4/3/17, Aldevron). Membranes were
probed with appropriated secondary antibodies conjugated to
horseradish peroxidase (HRP) (Dianova) and visualized by Pierce
ECLWestern Blotting Substrate (Thermo Scientific).
Colony Forming Assay in Soft Agar and
Suspension
Contact independent cell growth and colony formation were
tested by seeding cells in 0.2% sterile agarose/RPMI/FCS on
top of 0.5% sterile Noble agar/RPMI/FCS (bottom layer) as
described before (48). In brief, 1ml of 1% Noble Agar (BD
Biosciences) mixed with equal volume of 2 RPMI was
added to a 6-well plates and incubated at room temperature
for 30min. 2.5 103 cells were re-suspended in 2 RPMI,
mixed 1:1 with 0.4% agarose (41°C) (Bio-Budget), and seeded
on top of the solidified Noble-Agar. Five hundred microlitre
culture medium was added after solidification and replaced
with fresh medium every week. Each experiment was per-
formed in triplet. One centimeter square was photographed
utilizing Zeiss microscope (Zeiss AxioObserver.Z1), number
and diameter of colonies were determined by using ImageJ
software.
UKRV-Mel-15a cells (these cells do not form proper colonies
in soft agar) were cultured in medium for 5 days. Cell adhesion to
the culture plate was prevented by growing the cells on top of 0.5%
Noble Agar bottom layer (as described above).
Proteome Profiler Antibody Array
Serum-free conditionedmedia fromCEACAM1 isoform express-
ing Ma-Mel-86a melanoma cells were analyzed using a Proteome
Profiler Antibody Array (Human XL Cytokine Array Kit R&D
Systems) according to the manufacturer’s instructions. Briefly,
membranes were incubated overnight at 4°C in melanoma cell-
conditioned medium, washed twice and incubated 1 h at room
temperature with amixture of biotin-conjugated antibodies. After
incubation, membranes were washed twice and incubated with
HRP-conjugated antibodies. Bound secondary antibodies were
detected by enhanced chemiluminescence (ECL) reaction. Quan-
tification of signal intensities was performed using ImageQuant
software.
Adhesion Assay
UKE-Mel-1a cells were seeded onto 96-well plates coated with
collagen I (10μg/ml) (Sigma). Uncoated areas were blocked with
1%BSA/PBS for 30min. Cell adhesion was allowed to proceed for
45min. Non-adherent cells were removed by washing with PBS.
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Adherent cells were fixed with methanol and stained with 0.5%
crystal violet in 20% (v/v) methanol. The dye was released from
cells by addition of 1% SDS, and the absorbance of the dye solution
determined at 540 nm. The adhesion of the cells was expressed as
a percentage relative to mock transfectants.
Gelatin Zymography
Serum-free conditioned media were separated by gelatin zymog-
raphy as previously described (49). In brief, cells were grown
in FCS-free media for 24 h. Volumes of conditioned media
were normalized to cell number and fractioned on 10% SDS-
PAGE containing 1mg/ml gelatin (AppliChem). After elec-
trophoreses, gels were washed in 2.5% Triton-X 100 for 45min
and incubated overnight in substrate buffer (50mM Tris–HCl,
pH 8.0, 5mM CaCl2). Gels were stained with Coomassie
(BioRad).
Statistical Analysis
All results were shown as mean SEM. Student’s t-tests were
used to derive (two-sided) p-values for comparisons between
experimental groups. We applied a two-sided significance level α
of 5%. All calculations were performed by using the Graph Pad
Prism software (GraphPad software Inc., San Diego, CA, USA).
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